HBK Investments’s Travere Therapeutics TVTX Stock Holding History

HBK Investments’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-38,600	Closed	-$874K	–	1347
2018 Q4	$874K	Buy	+38,600	New	+$960K	0.01%	729
2018 Q3	–	Sell	-25,551	Closed	-$697K	–	1349
2018 Q2	$697K	Sell	25,551 -20,649	-45%	-$550K	﹤0.01%	719
2018 Q1	$1.03M	Buy	+46,200	New	+$1.1M	0.01%	613
2017 Q2	–	Sell	-35,407	Closed	-$654K	–	1027
2017 Q1	$654K	Buy	+35,407	New	+$693K	0.01%	479
2016 Q4	–	Sell	-12,995	Closed	-$291K	–	887
2016 Q3	$291K	Buy	+12,995	New	+$247K	﹤0.01%	729
2016 Q1	–	Sell	-29,305	Closed	-$565K	–	1125
2015 Q4	$565K	Buy	29,305 +8,305	+40%	+$166K	0.01%	715
2015 Q3	$425K	Buy	+21,000	New	+$622K	﹤0.01%	788

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HBK Investments's TVTX Position: Q1 2019 in Review

HBK Investments sold out of Travere Therapeutics (TVTX) in Q1 2019, closing a stake of 38,600 shares — an estimated $874K sold.

HBK Investments first reported a position in TVTX in Q3 2015 and held it in 7 quarters. The position peaked at $1.03M in Q1 2018. 131 funds tracked by Wall St. Rank hold TVTX as of Q1 2019.

HBK Investments reported no remaining Travere Therapeutics position as of Q1 2019 after selling out during the quarter.
HBK Investments sold 38,600 Travere Therapeutics shares in Q1 2019, an estimated $874K.
HBK Investments first reported a position in Travere Therapeutics in Q3 2015 and held it in 7 quarters.
HBK Investments's Travere Therapeutics position peaked at $1.03M in Q1 2018.
131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2019.

Based on HBK Investments's 13F filing for Q1 2019, filed 15 May 2019.